Dougald M Monroe

List of Publications by Year
in descending order

169 papers	10,501 citations	44069 48 h-index	32842 100 g-index
172 all docs	172 docs citations	172 times ranked	6565 citing authors

#	Article	IF	Citations
1	A Cell-based Model of Hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-965.	3.4	1,286
2	Platelets and Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1381-1389.	2.4	579
3	Platelet activity of highâ€dose factor VIIa is independent of tissue factor. British Journal of Haematology, 1997, 99, 542-547.	2.5	557
4	RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 2002, 419, 90-94.	27.8	492
5	A Systematic Evaluation of the Effect of Temperature on Coagulation Enzyme Activity and Platelet Function. Journal of Trauma, 2004, 56, 1221-1228.	2.3	424
6	The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients. Journal of Trauma, 2003, 55, 886-891.	2.3	415
7	A cell-based model of hemostasis. Thrombosis and Haemostasis, 2001, 85, 958-65.	3.4	348
8	What Does It Take to Make the Perfect Clot?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 41-48.	2.4	341
9	The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood, 2004, 104, 3858-3864.	1.4	259
10	Coagulation 2006: A Modern View of Hemostasis. Hematology/Oncology Clinics of North America, 2007, 21, 1-11.	2.2	219
11	A Cell-Based Model of Thrombin Generation. Seminars in Thrombosis and Hemostasis, 2006, 32, 032-038.	2.7	195
12	In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood, 2017, 129, 1021-1029.	1.4	183
13	Safety profile of recombinant factor VIIa. Seminars in Hematology, 2004, 41, 101-108.	3.4	170
14	Thrombin Activates Factor XI on Activated Platelets in the Absence of Factor XII. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 170-177.	2.4	169
15	Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. Journal of Thrombosis and Haemostasis, 2004, 2, 402-413.	3.8	153
16	Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood, 2003, 101, 3008-3013.	1.4	145
17	Current Concepts of Hemostasis. Anesthesiology, 2004, 100, 722-730.	2.5	130
18	The tissue factorâ€“factor VIIa complex: procoagulant activity, regulation, and multitasking. Journal of Thrombosis and Haemostasis, 2007, 5, 1097-1105.	3.8	130

#	Article	IF	Citations
19	High dose factor VIIa improves clot structure and stability in a model of haemophilia B. British Journal of Haematology, 2005, 131, 645-655.	2.5	127
20	High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. British Journal of Haematology, 2001, 114, 114-120.	2.5	126
21	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. American Journal of Hematology, 2000, 65, 30-34.	4.1	112
22	Cutaneous wound healing is impaired in hemophilia B. Blood, 2006, 108, 3053-3060.	1.4	104
23	Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagulation and Fibrinolysis, 1996, 7, 459-464.	1.0	100
24	Newer concepts of blood coagulation. Haemophilia, 1998, 4, 331-334.	2.1	100
25	Platelet procoagulant complex assembly in a tissue factor-initiated system. British Journal of Haematology, 1994, 88, 364-371.	2.5	99
26	Characterization of the Glycosaminoglycan-Binding Region of Lactoferrin. Archives of Biochemistry and Biophysics, 1995, 317, 85-92.	3.0	99
27	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood, 2014, 123, 1747-1756.	1.4	98
28	Tissue factor de-encryption. Blood Coagulation and Fibrinolysis, 1999, 10, 201-210.	1.0	92
29	Platelet Heterogeneity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 861-866.	2.4	89
30	The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 0373-0378.	2.7	87
31	Coagulation Factor IXa Binding to Activated Platelets and Platelet-Derived Microparticles: A Flow Cytometric Study. Thrombosis and Haemostasis, 1992, 68, 074-078.	3.4	81
32	Mechanism by which recombinant factor VIIa shortens the aPTT: Activation of factor X in the absence of tissue factor. Thrombosis Research, 1989, 56, 603-609.	1.7	79
33	Tissue factor around dermal vessels has bound factor VII in the absence of injury. Journal of Thrombosis and Haemostasis, 2007, 5, 1403-1408.	3.8	77
34	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology, 2001, 38, 6-9.	3.4	76
35	Superactivated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1747-1752.	2.4	71
36	Variability in platelet procoagulant activity in healthy volunteers. Thrombosis Research, 1996, 81, 533-543.	1.7	68

#	Article	IF	Citations
37	Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. Journal of Medical Genetics, 2017, 54, 338-345.	3.2	66
38	The Coagulation Cascade in Cirrhosis. Clinics in Liver Disease, 2009, 13, 1-9.	2.1	62
39	Novel mouse hemostasis model for realâ€time determination of bleeding time and hemostatic plug composition. Journal of Thrombosis and Haemostasis, 2015, 13, 417-425.	3.8	61
40	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood, 2020, 135, 755-765.	1.4	61
41	Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain.. Journal of Biological Chemistry, 1990, 265, 10250-10254.	3.4	58
42	A high affinity, antidoteâ€controllable prothrombin and thrombinâ€binding RNA aptamer inhibits thrombin generation and thrombin activity. Journal of Thrombosis and Haemostasis, 2012, 10, 870-880.	3.8	57
43	TFPIÎ², a Second Product from the Mouse Tissue Factor Pathway Inhibitor (TFPI) Gene. Thrombosis and Haemostasis, 1999, 81, 45-49.	3.4	56
44	Thrombin generation and cellâ€dependent hypercoagulability in sickle cell disease. Journal of Thrombosis and Haemostasis, 2016, 14, 1941-1952.	3.8	53
45	Structural Integrity of the Î³-Carboxyglutamic Acid Domain of Human Blood Coagulation Factor IXa Is Required for Its Binding to Cofactor VIIIa. Journal of Biological Chemistry, 1996, 271, 3869-3876.	3.4	51
46	Structure/Function Analyses of Recombinant Variants of Human Factor Xa:â€‰ Factor Xa Incorporation into Prothrombinase on the Thrombin-Activated Platelet Surface Is Not Mimicked by Synthetic Phospholipid Vesicles. Biochemistry, 1998, 37, 5029-5038.	2.5	50
47	Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood, 2002, 100, 539-546.	1.4	49
48	Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. Journal of Thrombosis and Haemostasis, 2006, 4, 2092-2093.	3.8	49
49	Abnormal hemostasis in a knockâ€in mouse carrying a variant of factorÂIX with impaired binding to collagen typeÂIV. Journal of Thrombosis and Haemostasis, 2009, 7, 1843-1851.	3.8	48
50	Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. Journal of Thrombosis and Haemostasis, 2004, 2, 1816-1822.	3.8	47
51	A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation. American Journal of Clinical Pathology, 1992, 98, 531-533.	0.7	46
52	Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. Journal of Thrombosis and Haemostasis, 2007, 5, 1577-1583.	3.8	44
53	Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood, 2016, 128, 286-292.	1.4	44
54	Molecular defect (Gla+14---Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").. Journal of Biological Chemistry, 1990, 265, 11982-11989.	3.4	44

#	Article	IF	Citations
55	An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase. Journal of Biological Chemistry, 2010, 285, 5212-5223.	3.4	42
56	Major burn injury is not associated with acute traumatic coagulopathy. Journal of Trauma and Acute Care Surgery, 2013, 74, 1474-1479.	2.1	41
57	Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. Blood, 2017, 129, 2161-2171.	1.4	40
58	The clotting system â€“ a major player in wound healing. Haemophilia, 2012, 18, 11-16.	2.1	39
59	The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagulation and Fibrinolysis, 2000, 11, S3-S7.	1.0	38
60	Deencryption of Cellular Tissue Factor Is Independent of Its Cytoplasmic Domain. Biochemical and Biophysical Research Communications, 2000, 272, 332-336.	2.1	38
61	Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies. Scientific Reports, 2019, 9, 15449.	3.3	38
62	Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.. Journal of Clinical Investigation, 1997, 100, 886-892.	8.2	38
63	Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. Journal of Biological Chemistry, 1990, 265, 10250-4.	3.4	38
64	Comparison of lipid binding and kinetic properties of normal, variant, and .gamma.-carboxyglutamic acid modified human factor IX and factor IXa. Biochemistry, 1985, 24, 8064-8069.	2.5	36
65	Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. British Journal of Haematology, 2006, 134, 314-319.	2.5	36
66	Mechanism of Action of High-Dose Factor VIIa. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 8-9.	2.4	33
67	Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 1995, 86, 1794-801.	1.4	33
68	Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thrombosis and Haemostasis, 1998, 80, 578-84.	3.4	33
69	Rethinking the coagulation cascade. Psychophysiology, 2005, 4, 391-6.	1.1	33
70	Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia. Blood, 2008, 111, 2046-2048.	1.4	31
71	Wound healing in haemophilia â€“ breaking the vicious cycle. Haemophilia, 2010, 16, 13-18.	2.1	31
72	FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood, 2014, 123, 1764-1766.	1.4	31

#	Article	IF	Citations
73	Mouse models of hemostasis. Platelets, 2020, 31, 417-422.	2.3	31
74	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	1.1	30
75	Rethinking the Coagulation Cascade. Japanese Journal of Thrombosis and Hemostasis, 2005, 16, 70-81.	0.1	28
76	Potent Anticoagulant Aptamer Directed against Factor IXa Blocks Macromolecular Substrate Interaction. Journal of Biological Chemistry, 2012, 287, 12779-12786.	3.4	28
77	Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg"). Journal of Biological Chemistry, 1990, 265, 11982-9.	3.4	28
78	Recombinant activated factor VII and the anaesthetist.. Anaesthesia, 2005, 60, 1203-1212.	3.8	27
79	Tissue Factor in Brain Is Not Saturated With Factor VIIa. Stroke, 2009, 40, 2882-2884.	2.0	27
80	Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thrombosis and Haemostasis, 2012, 107, 717-725.	3.4	27
81	Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate. Anesthesiology, 2015, 122, 353-362.	2.5	27
82	Use of p-aminobenzamidine to monitor activation of trypsin-like serine proteases. Analytical Biochemistry, 1988, 172, 427-435.	2.4	26
83	What Is Wrong With the Allosteric Disulfide Bond Hypothesis?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1997-1998.	2.4	25
84	Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Canadian Journal of Anaesthesia, 2002, 49, S7-14.	1.6	25
85	Wound healing in hemophilia B mice and low tissue factor mice. Thrombosis Research, 2010, 125, S74-S77.	1.7	24
86	Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. Journal of Thrombosis and Haemostasis, 2013, 11, 1043-1052.	3.8	23
87	Cellular Interactions in Hemostasis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 12-16.	0.3	22
88	Further Understanding of Recombinant Activated Factor VII Mode of Action. Seminars in Hematology, 2008, 45, S7-S11.	3.4	22
89	Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity. Journal of Thrombosis and Haemostasis, 2011, 9, 759-766.	3.8	22
90	Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitor. Thrombosis Research, 2012, 130, e151-e157.	1.7	22

#	Article	IF	Citations
91	Microplate coagulation assays. BioTechniques, 1992, 13, 430-3.	1.8	22
92	Modeling the action of factor VIIa in dilutional coagulopathy. Thrombosis Research, 2008, 122, S7-S10.	1.7	21
93	The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Disease-a-Month, 2003, 49, 14-21.	1.1	20
94	A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagulation and Fibrinolysis, 1998, 9 Suppl 1, S15-20.	1.0	20
95	Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity. Wound Repair and Regeneration, 2012, 20, 770-777.	3.0	19
96	The Effect of Active Site-inhibited Factor VIIa on Tissue Factor-initiated Coagulation Using Platelets before and after Aspirin Administration. Thrombosis and Haemostasis, 1997, 78, 1202-1208.	3.4	18
97	A mouse bleeding model to study oral anticoagulants. Thrombosis Research, 2014, 133, S6-S8.	1.7	16
98	Anticoagulation increases alveolar hemorrhage in mice infected with influenza A. Physiological Reports, 2016, 4, e13071.	1.7	16
99	In vitro characterization of <scp>MOD</scp>â€5014, a novel longâ€acting carboxyâ€terminal peptide (CTP)â€modified activated FVII. Haemophilia, 2018, 24, 477-486.	2.1	16
100	FactorÂXI promotes hemostasis in factorÂIXâ€deficient mice. Journal of Thrombosis and Haemostasis, 2018, 16, 2044-2049.	3.8	16
101	Impact of Nonâ€“Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1812-1818.	2.4	15
102	Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules.. Journal of Biological Chemistry, 1990, 265, 20907-20911.	3.4	15
103	Platelet activation in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 1993, 42, 182-185.	4.1	14
104	Links Between the Immune and Coagulation Systems: How Do "Antiphospholipid Antibodies" Cause Thrombosis?. Immunologic Research, 2000, 22, 191-198.	2.9	14
105	Activation of Protease-Activated Receptors 3 and 4 Accelerates Tissue Factorâ€“Induced Thrombin Generation on the Surface of Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2587-2596.	2.4	14
106	p-Amidino esters as irreversible inhibitors of factors IXa, Xa, and thrombin. Biochemistry, 1986, 25, 4929-4935.	2.5	13
107	Platelet binding and activity of recombinant factor VIIa. Thrombosis Research, 2010, 125, S16-S18.	1.7	13
108	Excessive breakthrough bleeding in haemophilia B patients on factor IXâ€albumin fusion protein prophylactic therapy: A single centre case series. Haemophilia, 2020, 26, e23-e25.	2.1	13

#	Article	IF	Citations
109	Arginine 200 of Heparin Cofactor II Promotes Intramolecular Interactions of the Acidic Domain. Journal of Biological Chemistry, 1997, 272, 14074-14079.	3.4	12
110	Characterization of IXINITYÂ® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph. Advances in Hematology, 2016, 2016, 1-9.	1.0	12
111	Thrombin generation in vascular tissue. Journal of Thrombosis and Haemostasis, 2006, 4, 60-67.	3.8	11
112	The Art and Science of Building a Computational Model to Understand Hemostasis. Seminars in Thrombosis and Hemostasis, 2021, 47, 129-138.	2.7	11
113	Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood, 1989, 73, 1540-4.	1.4	11
114	Platelets contain releasable coagulation factor IX antigen. Blood Coagulation and Fibrinolysis, 1993, 4, 905-910.	1.0	10
115	Cystamine Preparations Exhibit Anticoagulant Activity. PLoS ONE, 2015, 10, e0124448.	2.5	10
116	Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules. Journal of Biological Chemistry, 1990, 265, 20907-11.	3.4	10
117	Fathers of modern coagulation. Thrombosis and Haemostasis, 2007, 98, 3-5.	3.4	9
118	Models for assessing immunogenicity and efficacy of new therapeutics for the treatment of haemophilia. Haemophilia, 2012, 18, 43-47.	2.1	9
119	Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia, 2013, 19, 926-932.	2.1	8
120	Protease: Serpin complexes to assess contact system and intrinsic pathway activation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 789-798.	2.3	8
121	Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects. Journal of Colloid and Interface Science, 2020, 577, 406-418.	9.4	8
122	Role of the Î³-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. Journal of Thrombosis and Haemostasis, 2004, 2, 1127-1134.	3.8	7
123	Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?. Haemophilia, 2016, 22, 148-151.	2.1	7
124	Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood, 1992, 79, 398-405.	1.4	7
125	Comparison of the behavior of normal factor IX and the factor IX BM variant hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. American Journal of Hematology, 1993, 43, 177-182.	4.1	6
126	Platelet activation and its patient-specific consequences. Thrombosis Research, 2008, 122, 435-441.	1.7	6

#	Article	IF	Citations
127	A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. Journal of Thrombosis and Thrombolysis, 2009, 28, 132-139.	2.1	6
128	The multiple roles of tissue factor in wound healing. Frontiers in Bioscience - Scholar, 2012, S4, 713-721.	2.1	6
129	Plasmin Activation of Glial Cells through Protease-Activated Receptor 1. Pathology Research International, 2013, 2013, 1-8.	1.4	6
130	Structural and Enzymatic Properties of Escherichia coli Glutamine Synthetase Subjected to Limited Proteolysis. Current Topics in Cellular Regulation, 1985, 27, 361-372.	9.6	6
131	Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. Nature Communications, 2021, 12, 6912.	12.8	6
132	Factor VIIa: on its own and loving it. Blood, 2012, 120, 705-707.	1.4	5
133	Soluble Phosphatidylserine Binds to Two Sites on Human Factor IXa in a Ca2+ Dependent Fashion to Specifically Regulate Structure and Activity. PLoS ONE, 2014, 9, e100006.	2.5	5
134	Adding some muscle to blood coagulation. Blood, 2016, 128, 1786-1787.	1.4	5
135	Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. American Journal of Hematology, 2000, 65, 30-34.	4.1	5
136	Partial Reversal of Dabigatran Effect by a Prothrombin Complex Concentrate in a Model of Thrombin Generation. Blood, 2012, 120, 3420-3420.	1.4	5
137	Celecoxib does not delay cutaneous wound healing in haemophilia B mice. Haemophilia, 2009, 15, 615-616.	2.1	4
138	Inflammation does not predispose to bleeding in hemophilia. Journal of Thrombosis and Haemostasis, 2010, 8, 2583-2585.	3.8	4
139	Reversing targeted oral anticoagulants. Hematology American Society of Hematology Education Program, 2014, 2014, 518-523.	2.5	4
140	A novel one-step purification of mouse factor IX. Thrombosis Research, 2016, 139, 125-126.	1.7	4
141	Computationally Driven Discovery in Coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 79-86.	2.4	4
142	Calcium ion binding to human and bovine factor X. Blood Coagulation and Fibrinolysis, 1990, 1, 633-40.	1.0	4
143	Dysregulation of Hemostasis by Cancer. Cancer Treatment and Research, 2009, 148, 3-15.	0.5	3
144	Role of Gamma-Carboxyglutamic Acid (GLA) Domain in Phosphatidylserine (PS)-Regulated Activity of Factor IXa.. Blood, 2007, 110, 2696-2696.	1.4	3

#	Article	IF	Citations
145	Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa. Blood, 2018, 132, 1167-1167.	1.4	3
146	An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model. Journal of Thrombosis and Haemostasis, 2016, 14, 1249-1254.	3.8	2
147	Assessing the impact of product inhibition in a chromogenic assay. Analytical Biochemistry, 2019, 580, 62-71.	2.4	2
148	Histones Induce the Release of Extracellular Hemoglobin and Red Blood Cell-Derived Microvesicles with Procoagulant Activity. Blood, 2018, 132, 2514-2514.	1.4	2
149	Polyphosphates rock! A role in thrombosis?. Blood, 2015, 126, 1403-1404.	1.4	1
150	Coated platelet assay: a feasible approach to a complicated science. Haemophilia, 2016, 22, e67-e70.	2.1	1
151	VWF (von Willebrand Factor) Is Not Required for Red Blood Cell Retention in Clots in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1952-1954.	2.4	1
152	Abstract 288: Nitric Oxide Mediates Active Downregulation of Tissue Factor Expression in Human Pericytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	1
153	Delayed Wound Healing in Hemophilia B Mice.. Blood, 2005, 106, 3199-3199.	1.4	1
154	Reversal Of Dabigatran Anticoagulation By a 4-Factor Prothrombin Complex Concentrate: Correlation Between Effects On Parameters Of Thrombin Generation and Hemostatic Effect In Vivo. Blood, 2013, 122, 3643-3643.	1.4	1
155	Nontoxic Irreversible Inhibitors of Factors IXa, Xa, and Thrombin: Potential Therapeutic Agents for the in Vivo Regulation of Thrombin Generation and Activity. Annals of the New York Academy of Sciences, 1986, 485, 199-203.	3.8	0
156	Prothrombin times on deficient plasma reconstituted with factors IX and X. American Journal of Hematology, 1994, 47, 246-246.	4.1	0
157	More Information on Patients with Factor XI Deficiency. Anesthesiology, 2004, 101, 1253-1254.	2.5	0
158	Harold Ross Roberts, <scp>MD</scp>, 1930â€2017. Haemophilia, 2018, 24, 13-14.	2.1	0
159	A unique protein kinaseÂCâ€dependent pathway for tissue factor downregulation in pericytes. Journal of Thrombosis and Haemostasis, 2019, 17, 670-680.	3.8	0
160	EPCR knockout: inflaming the discussion. Blood, 2020, 135, 2201-2202.	1.4	0
161	Increased Platelet Binding of NN1731, a Factor VIIa Variant with Enhanced Tissue Factor-Independent Activity.. Blood, 2010, 116, 1133-1133.	1.4	0
162	The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation. Blood, 2011, 118, 541-541.	1.4	0

#	Article	IF	Citations
163	Downregulation Of Tissue Factor Expression In Human Pericytes In An Endothelial Cell Co-Culture Model. Blood, 2013, 122, 3524-3524.	1.4	0
164	Purified DNA, but Not Neutrophil Extracellular Traps (NETs), Promotes Contact Activation of Coagulation. Blood, 2015, 126, 767-767.	1.4	0
165	Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis. Blood, 2019, 134, 3623-3623.	1.4	0
166	Clinical Role of Recombinant Factor Vlla in Bleeding Disorders. , 2008, , 587-596.		0
167	Emizicumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner. Blood, 2021, 138, 3182-3182.	1.4	0
168	In Hemophilia Î‘ Plasma Treated with Emicizumab, Factor IX Activation By Factor VIIa Drives Thrombin Generation. Blood, 2020, 136, 17-17.	1.4	0
169	In Hemophilia Î‘ Plasma Treated with Emicizumab, Factor IXa in Activated Prothrombin Complex Concentrates Is the Dominant Contributor to Enhanced Thrombin Generation. Blood, 2020, 136, 16-17.	1.4	0